An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Trial Status: enrolling by invitation
The goal of this clinical study is to learn more about the long-term safety,
effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel,
brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in
participants of Kite-sponsored interventional studies.
Inclusion Criteria
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF)
or an Informed Assent Form prior to any study-related assessments or procedures
being conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Additional locations may be listed on ClinicalTrials.gov for NCT05041309.
